Spotlight On... JAMA study finds popular app for measuring blood pressure is inaccurate ; Zimmer launches trio of hip products; ConforMIS launches iTotal PS hip replacement; and more...

A study in the Journal of the American Medical Association determined that a best-selling mobile health app to estimate blood pressure produced many false negatives, giving users the incorrect impression that the metric was in the normal range when in fact it was dangerously high. AuraLife's Instant Blood Pressure app was downloaded at least 950 times per day for $4.99 between June 2014 and July 2015 before it was taken off the market (though the app could still be on patients' phones). Rather than using a standard blood pressure cuff, patients were instructed to place the top edge of their smartphone on their chest and put their right index finger on top of the device's camera. Newport Beach, CA's AuraLife does not appear in the FDA's approval databases, even though the app clearly meets agency's definition of a mobile health app that should be regulated because it performs the function of a traditional medical device and could pose a risk to a patient's safety if it does not work as intended. AuraLife CEO Ryan Archdeacon said the study is invalid, and that the software has been updated to improve accuracy by 30%. Here's the study | More

@FierceMedDev: IBM Watson unveils its first Apple ResearchKit effort with massive, patient-designed sleep study. Report | Follow @FierceMedDev

@EmilyWFierce: New York AG launches probe into insurers' coverage of hep C drugs--or lack thereof. More from FiercePharma | Follow @EmilyWFierce

> ConforMIS ($CFMS) has launched its iTotal PS, a customized posterior stabilized knee replacement system that it said nearly triples its potential market. More

> Zimmer Biomet ($ZBH) has launched three new hip products: the Echo Bi-Metric Microplasty Stem, G7 Dual Mobility Construct and Arcos One-Piece Revision System. More

> The FDA has approved Medtronic's ($MDT) Specify SureScan MRI surgical leads for use with its neurostim implant systems for chronic pain, which the company said gives it the first fully MR conditional system of this kind. More

Biotech News

@FierceBiotech: Still licking Duchenne wounds, BioMarin makes an early run at Batten drug OK. More | Follow @FierceBiotech

@JohnCFierce: Syndax braves a market tempest in second IPO try, scores a $53M raise. Article | Follow @JohnCFierce

> Alaska Fund acquires a taste for big biotech startups. Item

> Opexa sheds 30% of its workforce as it awaits make-or-break MS data. Story

> That priority review voucher program? The FDA hates it. More

> Pfizer, Merck KGaA partner PD-L1 drug with Verastem's failed cancer drug. Article

Pharma News

@FiercePharma: Dancing bladders and football-helmeted toenails have FDA questioning cartoons in DTC ads. More from FiercePharmaMarketing | Follow @FiercePharma

@CarlyHFierce: ICYMI: Don't give up on generic Copaxone, despite Teva's aggressive brand defense: Momenta CEO. Article | Follow @CarlyHFierce

> Head of Valeant's embattled dermatology unit exits in management shakeup. Article

> Trump's healthcare plan backs drug reimportation, but leaves out Medicare price negotiation. More

> Court document accuses J&J, Bayer of keeping mum about Xarelto lab data. Item

Pharma Manufacturing News

> McKesson extends its Canada supply chain reach with $2.23B deal for Rexall chain. Report

> Another of AmerisourceBergen's Pharmedium facilities cited by FDA. Story

> Bayer spending $2.7B on capacity expansion, outgoing CEO says. Article

> Essentra adding jobs in Wales with pharma packaging facility. More

> CutisPharma adds drug manufacturing to its operations. Item

CRO News

> Infinity taps CRO Pharm-Olam for a Phase II lymphoma study. Report

> PRA eyes double-digit growth in 2016 after a banner revenue year. Story

> Chinese CRO R&G buys into Medidata's trial tech. News

> Medpace signs on to help Actinium get its cancer drug into Phase III. More

> Synexus buys Research Across America, gaining first access to the U.S. Article

Pharma Asia News

> China's Shanghai Fosun Pharmaceutical eyes RMB3B bond issue. Report

> AstraZeneca moves quickly to shed another noncore drug in ProStrakan deal. Item

> HK-based Chi-Med doses first patient in China PhII thyroid cancer trial of sulfatinib. More

> South Korea's Yuhan finds U.S. partner Sorrento for immune checkpoint antibodies JV. Story

> Americas units of Japan's Olympus hit with penalties of $623M in kickback probe. Article